Basic Information
RYTMONORM TABLET 150 mg
TABLET, FILM COATED
Regulatory Information
SIN00395P
April 26, 1988
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XC01BC03
Company Information
ABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED
ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED
Active Ingredients
Strength: 150 mg
Detailed Information
Contraindications
**4.3. Contraindications** - Known hypersensitivity to propafenone hydrochloride or to any of the excipients - Known Brugada Syndrome (see **Special warnings and precautions for use** – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) - Incident of myocardial infarction within the last 3 months - Significant structural heart disease such as: - uncontrolled congestive heart failure where left ventricular output is less than 35% - cardiogenic shock (unless this is caused by arrhythmia) - severe symptomatic bradycardia - presence of sinus node dysfunction, atrial conduction defects, second degree or greater atrioventricular block or bundle branch block or distal block in the absence of an artificial pacemaker - severe hypotension - Manifest electrolyte imbalance (e.g. potassium metabolism disorders) - Severe obstructive pulmonary disease - Myasthenia gravis - Concomitant treatment with ritonavir
Indication Information
**4.1. Therapeutic indications** Symptomatic supraventricular tachyarrhythmias warranting treatment, such as AV junctional tachycardias, supraventricular tachycardias in patients with WPW syndrome or paroxysmal atrial fibrillation. Serious symptomatic ventricular tachyarrhythmias if life-threatening or necessitating treatment in the judgement of the physician.